University of Warwick

Firmly established as one of the UK’s top universities, the University of Warwick is renowned for being forward-looking and ambitious, with an acknowledged reputation for excellence in research and teaching.

Still a relatively young institution – established in 1965 – from the outset Warwick quickly became known for our entrepreneurialism and for building strong links with business and industry. Our reputation for employability, academic excellence and a desire to do things differently is reflected in our consistently high performance in Higher Education league tables. We are ranked 3rd most targeted university by UK’s top 100 employers (The Graduate Market in 2020, High Fliers Research), 8th in Europe for teaching and learning environment (Times Higher Education 2019), and 20th Most International University in the World (Times Higher Education 2021).

As a leading UK research institution, we are committed to research that is internationally recognised and impactful. Our researchers are inspired by fundamental questions led by our intellectual curiosity. They are supported to deliver provocative, interdisciplinary research which aims to create knowledge and transform the way we understand the world.

Warwick’s expertise currently spans 31 academic departments and more than 50 research centres and institutes across three Faculties: Arts; Science, Engineering and Medicine; and Social Sciences. Our Global Research Priorities are helping to improve the lives of people around the world by bringing our research teams from many different disciplines in order to tackle some of the most complex global challenges.

Learn more


    University of Warwick News

    Why big pharma needs little bio

    On 26 January, in London, Science|Business organised a roundtable of executives in the biotech industry to discuss the state of the market. The consensus: investor appetite for biotech companies is on the rise.
    01 Feb 2006

    Biotech brings silver lining to pharma cloud

    Last month the world's leading pharmaceutical company received simultaneous FDA approval for two new therapies. Yet neither drug was invented by the company. Both were originally developed by small biotechs.
    01 Feb 2006

    Aho: Europe must close the rhetoric gap

    "There is a large gap between the rhetoric of a political system that preaches the Knowledge Society and the reality of budgetary and other priorities that have shown little shift in preparing to engage with it." Esko Aho, former Prime Minister of Finland, in Creating an Innovative Europe, January 2006.
    01 Feb 2006

    Europe must close the rhetoric gap

    Europe preaches the knowledge society, but its aversion to risk and reluctance to change has got to go, warns Esko Aho, former prime minister of Finland.
    01 Feb 2006

    Last chance for European nanomedicine

    Nanotechnology has the power to transform healthcare. But Europe will lose out to the United States unless it can mount a coherent approach to developing nanomedicine, says a new report.
    01 Feb 2006